Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Penault-Llorca

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Gynecologic Oncology|April 8, 2022
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)S Henno, C Jeanne, T De La Motte Rouge, et al.
British Journal of Cancer|May 8, 2014
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic studyM-C Etienne-Grimaldi, A Mahamat, M Chazal, et al.
ESMO Open|June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06R Shami, R Salgado, A Bardia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactJ M Nabholtz, C Abrial, M A Mouret-Reynier, et al.
ESMO Open|May 13, 2021
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in FranceJ Y Blay, S Boucher, B Le Vu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Gynecologic Oncology|April 8, 2022
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)S Henno, C Jeanne, T De La Motte Rouge, et al.
British Journal of Cancer|May 8, 2014
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic studyM-C Etienne-Grimaldi, A Mahamat, M Chazal, et al.
ESMO Open|June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06R Shami, R Salgado, A Bardia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactJ M Nabholtz, C Abrial, M A Mouret-Reynier, et al.
ESMO Open|May 13, 2021
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in FranceJ Y Blay, S Boucher, B Le Vu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP Tarantino, G Viale, M F Press, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 12